Showing results (291-300 of 324) with videos related to
Sort By:
Pageof 33
Acta Neuropathologica|July 20, 2021
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated stateVeena Kochat, Ayush T Raman, Sharon M Landers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.Med (New York, N.Y.)|July 29, 2026
Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanomaLilit Karapetyan, Jin Xu, Kimberly Ward, et al.Nature Communications|April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.Nature Communications|July 9, 2022
Multi-modal molecular programs regulate melanoma cell stateMiles C Andrews, Junna Oba, Chang-Jiun Wu, et al.Pageof 33